多发性骨髓瘤中的第二原发恶性肿瘤:概述与IMWG共识
国际骨髓瘤工作组(IMWG)专家小组回顾截至2016年6月发表的相关文献,概述多发性骨髓瘤患者第二原发恶性肿瘤(SPM)的宿主、疾病和治疗相关危险因素,并提供实践推荐。总体SPM风险低且多因素,来那度胺联合口服美法仑(序贯或同时)时SPM发生率显著增加,但骨髓瘤死亡风险仍显著高于SPM死亡风险。
要点
- 多发性骨髓瘤患者总体SPM风险低,呈多因素性,部分与生存期延长及骨髓瘤内在易感性相关。
- 来那度胺联合口服美法仑(序贯或同时)时SPM发生率显著增加,来那度胺维持治疗(高剂量美法仑后)也有增加但程度较轻。
- 上述情况下骨髓瘤死亡风险显著高于SPM死亡风险,来那度胺可能提供生存获益。
核心结论
- 总体而言,SPM风险不应改变当前多发性骨髓瘤的治疗决策过程。
- 来那度胺联合地塞米松方案应优先于长期暴露于来那度胺联合口服美法仑。
- 应与患者在不同治疗方案的获益与风险背景下仔细讨论SPM风险。
研究设计与样本
- 国际骨髓瘤工作组(IMWG)专家小组对截至2016年6月发表的全文论文或在美国临床肿瘤学会、美国血液学会、欧洲血液学协会或国际骨髓瘤工作组会议上展示的最相关数据进行文献回顾,并基于此提出推荐。
主要发现
- 总体而言,多发性骨髓瘤中SPM风险低、呈多因素性,部分与患者生存期长度及骨髓瘤内在易感性相关。
- 研究提示,来那度胺在口服美法仑之后或与口服美法仑同时给药时,SPM发生率显著增加。
- 在高剂量美法仑后来那度胺维持治疗中也有SPM发生率增加的报道,但程度较轻。
- 在上述两种情况下,骨髓瘤死亡风险显著高于SPM死亡风险,来那度胺可能提供生存获益。
- 来那度胺联合地塞米松(不含美法仑)、或硼替佐米联合口服美法仑、地塞米松或沙利度胺未见SPM发生率增加的报告。
临床怎么用
- 总体而言,SPM风险不应改变当前多发性骨髓瘤的治疗决策过程。
- 来那度胺联合地塞米松方案应优先于长期暴露于来那度胺联合口服美法仑。
- 应与患者在不同治疗方案的获益与风险背景下仔细讨论SPM风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians. DESIGN: A Panel of International Myeloma Working Group members reviewed the most relevant data published in the literature as full papers, or presented at meetings of the American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, or International Myeloma Workshops, up to June 2016. Here, we present the recommendations of the Panel, based on this literature review. RESULTS: Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide. CONCLUSION: In general, the risk of SPMs should not alter the current therapeutic decision-making process in MM. However, regimens such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to lenalidomide plus oral melphalan. SPM risk should be carefully discussed with the patient in the context of benefits and risks of different treatment options.
引用
- Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017. PMID: 27864218. doi:10.1093/annonc/mdw606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。